Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

The standard of care (SoC) for Large Cell Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, its ideal dose intensity varies among cases.
Miura et al. 2022 Expert Review of Anticancer Therapy 22(6): 583-595

Although several novel therapies have gained regulatory approval for the treatment of DLBCL, there remains a need for additional therapies to enhance the current treatment landscape.
Ahmeda & H…

References (Sources)

Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist
Jacobson et al. 2020
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
Di et al., 2021
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Ahmeda & Hamadani 2021 Expert Review of Anticancer Therapy 21(12): 1313-1320
Review
Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma
Miura et al. 2022 Expert Review of Anticancer Therapy 22(6): 583-595
Review
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca & Gaidano 2021 Expert Opinion on Investigational Drugs 30: 25-38
Review
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Caimi et al. 2021 The Lancet Oncology 22: 790-800
Precision Medicine in DLBCL: Are We There Yet?
Davies 2021

AI Chat

7/1/2026

Chat with our artificial intelligence: